- Gastroenterology Advisor

1971 to 2017 Saw 32 Drinking Water Hepatitis A Outbreaks

Thirty-two outbreaks of hepatitis A associated with drinking water were identified during 1971 to 2017, and all occurred before 2010.

Mycophenolate Mofetil Does Not Top Methotrexate in Noninfectious Uveitis

For adults with noninfectious uveitis, mycophenolate mofetil is not associated with superior control of inflammation compared with methotrexate.

FDA: Cases of Serious Liver Injury Reported With Certain HCV Agents

By

Diana Ernst, RPh

The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.

PCT manifests when hepatic UROD activity is <20% of normal.1 As porphyrins accumulate in the liver, they are transported to the skin, leading to phototoxicity as light exposure causes the porphyrins to release photons.1 Subsequently, patients develop blisters on sun-exposed areas of their skin, particularly the hands, face, neck, and forearms. These areas are also prone to blisters and peeling after mild trauma. When the lesions scar, they may resemble systemic scleroderma. In some cases, lesions become painful. Patients may also have abnormal hair growth, skin thickening, and hypopigmentation. PCT is diagnosed when elevated porphyrins are detected in the plasma. Urine and fecal studies can confirm the diagnosis when they show similarly elevated porphyrin levels, with urine typically showing excess uroporphyrin and 7-carboxylate porphyrin and feces showing excess isocoproporphyrin.6 Patients with a PCT diagnosis should be tested for HCV if their status is unknown. Photo Credit: Dr Harout Tanielian/Science Source.

Patients With Porphyria Cutanea Tarda Have Higher Mortality Risk

By

Brandon May

Patients with porphyria cutanea tarda have increased all-cause mortality and risk for death because of gastrointestinal diseases and cancer of the gut, liver, gallbladder, and lungs.

FDA Reports Rare Cases of Liver Injury, Failure With Hep C Therapies

FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.

Novel Synthetic Bio Drug for Hyperammonemia Granted Fast Track

By

Steve Duffy

Synthetic Biotic medicines utilize synthetic biology to reprogram probiotic bacteria to perform critical functions that compensate for those missing or damaged due to a particular disease.

Comorbidity Burden Predicts 6-Month Mortality in Suspected Drug-Induced Liver Injury

By

Gastroenterology Advisor Contributing Writer

Researchers identified a strong relationship between significant comorbidity burden and outcomes of patients with suspected drug-induced liver injury, and developed and validated a model to calculate risk of death within 6 months.

GLOBE, UK-PBC Models Predict Cirrhosis-Related Complications in Primary Biliary Cholangitis

By

Gastroenterology Advisor Contributing Writer

Two risk stratification models, GLOBE and UK-PBC, performed well in predicting future complications related to cirrhosis in patients with primary biliary cholangitis.

Impacts of Hypercholesterolemia and Statin Use in Cirrhosis

By

Rita Aghjayan

A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.

T2D a Risk Factor for Liver Fibrosis Progression in Nonalcoholic Fatty Liver Disease

Type 2 diabetes mellitus (T2DM) is a risk factor for progression of liver fibrosis in patients with nonalcoholic fatty liver disease.

Chronic liver disease

Latest News